AUCTORES
Globalize your Research
Case Report | DOI: https://doi.org/10.31579/2690-4861/051
*Corresponding Author: Pankaj Bansal, Mayo Clinic Health System. 1400 Bellinger Street, Eau Claire, WI.
Citation: Austin C, Pankaj B, Bhavin S, Amandeep G. (2020) Timeline of COVID-19 and its therapeutics in the United States. International Journal of Clinical Case Reports and Reviews. 3(3); DOI: 10.31579/2690-4861/051
Copyright: © 2020 Pankaj Bansal, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 18 August 2020 | Accepted: 04 September 2020 | Published: 07 September 2020
Keywords: covid-19, United States
The novel coronavirus was first discovered and reported in December 2019. Later termed the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COv-2) virus, rapid spread was detected in China. Overtime, SARS-COv-2 spread to various other countries requiring swift intervention on a global scale. As infection spread, several therapeutics have been investigated for Coronavirus Disease- 2019 (COVID-19), including remdesivir, lopinavir/ritonavir, hydroxychloroquine, dexamethasone, etc. Furthermore, rapid investigation and construction of several potential vaccines have begun, some of which are in late stage testing. We present a concise timeline representing the evolution of COVID-19, therapeutic trials, and vaccine development. Ultimately, evident by the overall poor efficacy of several medications investigated so far, vaccination success remains the most likely effective step to combat COVID-19.
The world is going through unprecedented times as the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus has continued its spread globally. It was in December 2019 that China alerted the World Health Organization (WHO) of a cluster of cases of pneumonia of unknown origin in the Wuhan in Hubei province [1]. While it was initially postulated that the human-to-human transmission may not exist, within a few days, the WHO confirmed the human-to-human transmission of the virus. Thailand reported the first imported case outside China on January 13th, 2020. On January 20th, the first case of 2019 novel coronavirus (2019-nCoV) was reported in the United States [2]. By January 30th, China had reported more than 9,000 cases with more than 200 deaths, and cases were reported from several other countries including Thailand, Japan, Taiwan, Singapore, Vietnam, Nepal, Finland, Italy, South Korea, India, Australia, France, Malaysia, and Canada [1]. It was on January 30th that the WHO declared the 2019-nCoV as a public health emergency of international concern [1].
The first mortality in the United States was reported on February 6th, 2020 from California [3]. On February 11 2020, the WHO announced the formal name Coronavirus Disease- 2019 (COVID-19) [4]. While the initial caseload and deaths were mostly in China, by the end of February 2020, Iran and European countries including Italy and France started reporting rising numbers of cases and deaths from COVID-19. By March 1st, most cases in the United States were from Washington State, and new cases were being reported from other states including New York. On March 11th, the WHO declared COVID-19 a pandemic and on March 13th, the United States declared the pandemic to be a national emergency [1].
The caseload in the United States crossed 100 on March 3rd 2020, and by March 19th 2020, the cases had surpassed 10,000 and on March 26th 2020, the United States overtook China to become the country with the most number of cases worldwide with more than 86,000 cases. It took less than a week to surpass 200,000 cases in the United States, and most of the cases were being reported from the New York area. On April 11th, 2020, with more than 19,000 deaths reported, the United States became the country with most deaths worldwide and by the end of April 2020, there were more than 1 million cases of COVID-19 in the United States [1]. This number steadily climbed in the United States and world eventually reaching 1,507,773 cases and 90,113 deaths in the United States, and 4,722,319 cases and 313,268 deaths worldwide by May 17th 2020 [5, 6]. Since April 2020, the United States has been the world leader in both the number of cases, as well as the number of deaths.5 As of August 5th 2020, when comparing the case-fatality ratios, the United States places 24 with the United Kingdom taking the lead. When investigating per capita death rates, the United States places ninth with Belgium placing first [7]. As of August 9th, the United States had 5,199,444 total cases with 165,617 deaths (Figure 1) [8, 9].
To date, there is no definitely proven effective therapeutic option for COVID-19. Initial attempts by scientists across the world have focused on finding therapeutic options already approved for another indication, and antiviral agents including lopinavir/ritonavir gained popularity owing to the in vitro efficacy against the Sudden Acute Respiratory Syndrome Coronavirus (SARS-CoV) and potential efficacy shown previously against Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) and Sudden Acute Respiratory Syndrome (SARS). However, further clinical trials failed to show any efficacy of lopinavir/ritonavir in COVID-19 [10, 11]
Similarly, antimalarial agents including chloroquine and hydroxychloroquine were one of the initial agents that gained interest as a therapeutic option after data from in-vitro studies and a cohort study from France showed potential antiviral efficacy [12]. The President of the United States in a press release famously cited this study [13], and antimalarial agents gained fame as potential game-changers. However, more well-performed studies and randomized controlled clinical trials soon followed and did not show any benefit of chloroquine or hydroxychloroquine in COVID-19, and the FDA retracted the emergency authorization for use of hydroxychloroquine in COVID-19 in June 2020 [11, 14-16]
One of the antiviral agents that has shown promise is remdesivir, a broad-spectrum antiviral agent. While initially developed for the treatment of hepatitis C, remdesivir has shown activity against SARS and MERS in past in vitro assays [17, 18]. This sparked investigation for a possible role in COVID-19. This medication was used on the first known COVID-19 case of the United States.19 After successful evidence showing moderate benefit especially in shortening the length of hospital stay in patients admitted with COVID-19, the FDA issued an emergency use authorization for remdesivir. It is currently the only drug still granted this approval for use in COVID-19 [17, 20-22].
COVID-19 is associated with excessive uncontrolled release of proinflammatory cytokines in severe cases, and several anti-inflammatory and immunomodulatory agents have been investigated, with trials ongoing on others. Data from the Rheumatology COVID registry revealed that patients who are already on moderate to high doses of corticosteroids have a higher risk of more severe COVID-19 infection [23, 24]. However, when used in more severe cases already needing oxygen, dexamethasone was shown to reduce mortality [25, 26]. Initial and preliminary data on other anti-inflammatory and immunomodulatory agents including interleukin-6 and interleukin-1 inhibitors (tocilizumab and anakinra respectively) have shown promising results, with further trials ongoing. Sarilumab, another interleukin-6 inhibitor did not show any benefit in COVID-19, while trials on colchicine, baricitinib, and anti-tumor necrosis factor medications are ongoing [27-29].
With no definite therapeutic agent still available, the hopes to overcome the pandemic rely mostly on a safe and effective vaccine. The goal of vaccination is to stimulate a protective immune response using viral genetics, proteins, or entire inactivated virions. Initial investigation of vaccines began rapidly, and several pharmaceutical companies have reached various stages of clinical trials by now. Many vaccine candidates have been established in all various roles described. Notably, Chinese based vaccines demonstrated a positive preliminary phase 1 results as early as May 22nd. Other vaccines followed closely with their own successful preliminary positive results. At this time, few vaccine candidates have entered phase III clinical trials [30-35]. possible viral mutations could interfere with the overall effectiveness of future vaccines, and further ongoing research about the viral evolution will be critical to investigate this complicating factor [36].
The United States-based Moderna vaccine that is mRNA based entered phase III in July 2020. Another mRNA based vaccine from the United States-based Pfizer/BioNTech has reached Phase II/III. China-based Sinopharm and Sinovac biotech have entered phase III with their vaccines using attenuated whole-virus inoculation, while the China based CanSinoBio and AstraZeneca have entered phase III with their viral vector based vaccines [30-35]. It may not be until 2021 that an effective and safe vaccine may be available for widespread use, and with no definite therapeutic option available. To date, the only way to mitigate the virus is by prevention precautions and social distancing.
Conclusion
Currently, no medications have sufficiently stood out as an outstanding therapeutic option for COVID-19, and trials on several potential vaccine candidates are ongoing worldwide, with a hope for a successful vaccine available for widespread use by 2021. Implementing prevention precautions remains as the primary method for limiting the spread of SARS-CoV-2.
Author contributions
All authors have made substantial contributions to the creation of this manuscript including writing the initial manuscript, literature review, and reviewing, and revising the final version. The final manuscript has been reviewed and approved by all authors.
Financial disclosure and conflict of interest statement
We confirm that the authors have no financial disclosures, competing interests, and conflict of interest. The study has not received any financial support or other benefits from commercial sources for the work reported on in the manuscript. The manuscript represents the original work of the authors and identical or similar work has not been published or submitted for publication elsewhere.
Data sharing statement
There is no data in this work.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
